Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide

Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradia...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Gerstner, Elizabeth R., Eichler, April F., Plotkin, Scott R., Drappatz, Jan, Doyle, Colin L., Xu, Lei, Duda, Dan G., Wen, Patrick Y., Jain, Rakesh K., Batchelor, Tracy T.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2010
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4090923/
https://ncbi.nlm.nih.gov/pubmed/20821342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0390-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky